By Rebecca Spalding
Roivant Sciences Ltd. raised $200 million in a new funding round that makes it one of the most highly valued private firms in the history of the biotechnology industry.
Most of the former BNP bankers are based in Hong Kong, with the remainder in Singapore.
SoftBank agreed to pay $3 billion to WeWork for the opportunity to buy shares before September 2019 at a price of $110 a share or higher, depending on whether WeWork goes public, is acquired or raises a $1 billion round before that date.
AustralianSuper is keen to extend loans of up to $360.3 million per asset in developed markets.
Hastings Asset Management, Daesung Private Equity, Sejong Venture Partners and Samsung Venture investment were the lead investors.
Moderna, valued at $7.5 billion, secured $500 million in a round participated by Singapore-based EDBI and Sequoia Capital China in February.
Nomura Holdings Inc and Daiwa Securities Group Inc will lead the sales effort for Japan’s biggest initial public offering ever, the sale of stock in SoftBank Group Corp’s domestic wireless operation.
SoftBank could consider purchasing a minority stake in Saudi Electricity from the Public Investment Fund (PIF) sovereign wealth fund.
The Asia Pacific Cities Fund has identified 17 cities, including Tokyo, Sydney, Brisbane, Singapore and Seoul, for investments.
The rejections crush what BGH had hoped would be its first purchases since it was set up last year by former local heads of U.S. private-equity giant TPG Capital Management and Australia’s Macquarie Group.